There is limited evidence for oligometastatic radiotherapy after EGFR mutation‐positive NSCLC targeted therapy, but it is unclear what kind of patients are the dominant population and the time of oligoprogression, and whether radiotherapy technology has an effect on efficacy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.